Podcast Episodes
Back to SearchUpdates, challenges and novel agents being explored in BPDCN
Episode 231
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive and rare hematological malignancy associated with poor prognosis. Several chall…
2 years, 8 months ago
Unanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadruplets
The treatment and management of patients with multiple myeloma is continually evolving, giving rise to novel prognostic tools and therapeutic options…
2 years, 8 months ago
Unanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadruplets
Episode 230
The treatment and management of patients with multiple myeloma is continually evolving, giving rise to novel prognostic tools and therapeutic options…
2 years, 8 months ago
Key updates in sickle cell disease at ASH 2023: disease biology, ongoing trials & the growing role of gene therapy
In recent years, the treatment landscape of sickle cell disease (SCD) has been revolutionized with the introduction of novel agents, including recent…
2 years, 8 months ago
Key updates in sickle cell disease at ASH 2023: disease biology, ongoing trials & the growing role of gene therapy
Episode 229
In recent years, the treatment landscape of sickle cell disease (SCD) has been revolutionized with the introduction of novel agents, including recent…
2 years, 8 months ago
ASH 2023 highlights: updates in the diagnosis and treatment of amyloidosis
In recent years, the treatment and management of light chain (AL) amyloidosis has transformed with the introduction of novel agents. While diagnosis …
2 years, 9 months ago
ASH 2023 highlights: updates in the diagnosis and treatment of amyloidosis
Episode 228
In recent years, the treatment and management of light chain (AL) amyloidosis has transformed with the introduction of novel agents. While diagnosis …
2 years, 9 months ago
MPN highlights at ASH 2023: novel agents & ongoing clinical trials in ET, PV and MF
The treatment of the BCR-ABL1-negative myeloproliferative neoplasms (MPNs), including myelofibrosis (MF), polycythemia vera (PV) and essential thromb…
2 years, 9 months ago
MPN highlights at ASH 2023: novel agents & ongoing clinical trials in ET, PV and MF
Episode 227
The treatment of the BCR-ABL1-negative myeloproliferative neoplasms (MPNs), including myelofibrosis (MF), polycythemia vera (PV) and essential thromb…
2 years, 9 months ago
iwNHL 2023 Session V: Expanding the CAR platform in NHL
The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed …
2 years, 9 months ago